VANCOUVER, Sept. 12, 2011 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") is pleased to announce that Health Canada has
approved its advanced wound care product Collexa®. Collexa® is
exclusively licensed to Merus Labs by Innocoll for sales and
distribution in Canada.
Collexa is an advanced bilayer wound care device comprising a layer of
white collagen matrix with a backing layer of absorbent polyurethane
foam. The collagen matrix layer aids in the wound management while the
polyurethane foam layer acts as a reservoir absorbing wound fluids.
Collexa can absorb greater than ten times its own weight in wound
Collexa may be used for the management of wounds including: Diabetic
ulcers, venous ulcers, pressure ulcers, ulcers caused by mixed vascular
etiologies, full thickness & partial thickness wounds, abrasions,
traumatic wounds, 1st and 2nd degree burns and surgical wounds.
Including Collexa®, Merus currently has 8 wound care products that will
be launched in the current quarter. "With the approval of Collexa®,
Merus will provide Canadian patients with a stronger pipeline of
products designed to greatly advance wound care treatment. We greatly
appreciate the diligent work of our partners Innocoll and Methapharm in
advancing the approval of Collexa® and launch of our line of wound care
products in this quarter." said Ahmad Doroudian, President and CEO.
About Merus Labs International Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition
and licensing of pharmaceutical products. The Company utilizes its
expertise in the North American pharmaceutical markets and its access
to capital to acquire and license niche branded products in Canada and
United States. Merus further enhances the sale and distribution of
these products by introduction of a focused marketing and promotion
About Innocoll Inc: Innocoll is an international biopharmaceutical company focused on
targeted delivery products primarily in the areas of biodegradable
surgical implants and topically applied healthcare products. The
company has developed and manufactures a range of pharmaceutical
products and medical devices using their proprietary collagen-based
This press release may contain forward-looking statements that involve
risks and uncertainties. These statements relate to future events or
our future financial performance. In some cases, you can identify
forward-looking statements by terminology including "could", "may",
"will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential" and the negative of these terms or
other comparable terminology. While these forward-looking statements,
and any assumptions upon which they are based, are made in good faith
and reflect our current judgment regarding the direction of our
business, actual results will almost always vary, sometimes materially,
from any estimates, predictions, projections, assumptions or other
future performance suggested in this report. Except as required by
applicable law, we do not intend to update any of the forward-looking
statements so as to conform these statements to actual results.
Investors should refer to the risks disclosed in the Company's reports
filed from time to time with securities regulatory authorities.
SOURCE Merus Labs International Inc.
For further information:
Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783